Abstract | BACKGROUND: METHODS: The study included 14 pediatric patients and five adult patients with Coats' disease. They were treated with intravitreal bevacizumab (1.25 mg/0.05 ml) as the initial treatment, combined with or without other treatments. The analyses included the evaluation of basic clinical conditions. RESULTS: In the pediatric group, after a mean of 9.1 months of follow-up, the differences in visual acuity were significant for the comparisons between the baseline examination and the follow-up examinations carried out at weeks 6, 12, and 24 after the baseline (P = 0.006, P = 0.004, P = 0.005 respectively). Vitreoretinal fibrosis was observed in three patients (n = 3, 21.4 %), among whom two showed fibrosis before treatment. All of the pediatric patients showed a resolution of fluid and exudation, and regression of the telangiectasia. In the adult group, after a mean of 10.6 months of follow-up, the differences in visual acuity were not statistically significant (P > 0.05) between the baseline and follow-up examinations. Vitreoretinal fibrosis (n = 2, 40 %) was observed in two patients who both showed fibrosis before treatment. All of the adult patients showed a resolution of fluid and exudation, and regression of the telangiectasia. The differences in the change of BCVA between children and adults were not significant (P > 0.05) during the follow-up examinations. CONCLUSION:
|
Authors | Xiao-Xue Zheng, Yan-Rong Jiang |
Journal | Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
(Graefes Arch Clin Exp Ophthalmol)
Vol. 252
Issue 1
Pg. 35-42
(Jan 2014)
ISSN: 1435-702X [Electronic] Germany |
PMID | 23873253
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Bevacizumab
|
Topics |
- Adult
- Angiogenesis Inhibitors
(therapeutic use)
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Bevacizumab
- Child
- Child, Preschool
- Female
- Fibrosis
- Fluorescein Angiography
- Follow-Up Studies
- Humans
- Intravitreal Injections
- Male
- Middle Aged
- Multimodal Imaging
- Ophthalmoscopy
- Retina
(pathology)
- Retinal Telangiectasis
(diagnosis, drug therapy)
- Retrospective Studies
- Tomography, Optical Coherence
- Ultrasonography
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
(physiology)
- Vitreous Body
(pathology)
- Young Adult
|